Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$9,085 Mln
Revenue (TTM)
$168 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
33
Industry P/E
--
EV/EBITDA
-20.9
Div. Yield
0 %
Debt to Equity
0.9
Book Value
$--
EPS
$-0.8
Face value
--
Shares outstanding
84,978,881
CFO
$-305.72 Mln
EBITDA
$-402.86 Mln
Net Profit
$-360.30 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Verona Pharma - ADR
| 130.2 | 0.6 | 16.8 | 234.0 | 117.4 | 77.5 | -- |
|
BSE Sensex*
| -15.3 | -11.8 | -15.8 | -5.7 | 6.7 | 7.5 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Verona Pharma - ADR
| 132.0 | -23.9 | 288.8 | -4.0 | 21.7 | -40.2 | -18.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Verona Pharma plc, a biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company offers Ohtuvayre, a dual inhibitor of the phosphodiesterase... (PDE) 3 and PDE4 enzymes that combines bronchodilator and non-steroidal anti-inflammatory effects for the maintenance treatment of chronic obstructive pulmonary disease, as well as cystic fibrosis and asthma. Verona Pharma plc was formerly known as Isis Resources plc and changed its name to Verona Pharma plc in September 2006. The company was incorporated in 2005 and is based in London, the United Kingdom. As of October 7, 2025, Verona Pharma plc operates as a subsidiary of Merck Sharp & Dohme LLC. Read more
President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
Headquarters
London
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Verona Pharma plc - ADR is $106.91 (NASDAQ) as of 07-Oct-2025 09:30 EDT. Verona Pharma plc - ADR has given a return of 117.36% in the last 3 years.
Since, TTM earnings of Verona Pharma plc - ADR is negative, P/E ratio is not available.
The P/B ratio of Verona Pharma plc - ADR is 33.01 times as on 05-Nov-2025, a 738 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-27.80
|
18.82
|
|
2023
|
-37.42
|
6.40
|
|
2022
|
-34.73
|
8.56
|
|
2021
|
-9.80
|
2.72
|
|
2020
|
-8.50
|
2.19
|
The 52-week high and low of Verona Pharma plc - ADR are Rs 106.93 and Rs 31.09 as of 02-Apr-2026.
Verona Pharma plc - ADR has a market capitalisation of $ 9,085 Mln as on 05-Nov-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Verona Pharma plc - ADR, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.